A recent study indicates that patients who discontinue popular GLP-1 drugs like Mounjaro or Wegovy can put back on lost weight much more quickly than those who stop traditional lifestyle programs.
Findings released in a major medical journal points out that while obese people frequently drop about a fifth of their body weight while undergoing treatment, the mass returns at an estimated rate of nearly a kilo each month upon discontinuation.
"Individuals using such drugs should be aware of the danger of fast rebound weight gain when the medication ends," cautioned researcher Dr. Susan Jebb.
That rate of recovery means a return to pre-treatment mass within about one and a half years.
Weighing Therapies
The analysis, which looked at 37 of trials involving over 9,000 of patients, compared the results of GLP-1 agonists with older methods.
The team note that people who lose weight through dieting usually experience a slower creep back—approximately 100 grams monthly—after stopping.
Understanding the Rapid Regain
Doctors suggest the mechanism of the drugs explains the amplified regain.
These medications mimic a natural hormone called GLP-1, which moderates appetite.
"Sustained high doses of the hormone levels far above than normal may cause the system to produce less of its endogenous hormone, and may also diminish sensitivity to its effects," noted Dr. Adam Collins, a dietetics expert.
"Discontinuation of this GLP-1 'fix' means appetite is no longer kept in check, making excessive eating much more probable."
A Lifelong Condition?
The NHS suggest the injections for people with obesity-related health risks, accompanied by recommended diet and exercise modifications.
Many experts contend that, given the likelihood of relapse, the therapy should be considered life-long.
This perspective is reinforced by pharmaceutical companies, who note that the findings "underscore the chronic nature of obesity," comparing it to managing conditions like high blood pressure.
Patient Accounts
Individuals who have discontinued the medication report a intense return of hunger.
"I experienced a trigger flipping and you're instantly extremely hungry," said a patient.
The struggle is exacerbated if patients have not developed sustainable dietary or behavioural changes during therapy.
Widespread Use
Figures indicate that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with interest remaining high.
- Adoption is more common among women than males.
- The 40s and 50s age group shows the highest usage rates.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
In conclusion, clinicians stress that while these medications are potent tools for weight loss, they are not a standalone cure and lasting health benefits hinges on integrated behavioural support.
